{"id":"ketanserin","rwe":[],"tags":[{"label":"ketanserin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"SIGMAR1","category":"gene"},{"label":"HTR1F","category":"gene"},{"label":"C02KD01","category":"atc"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=KETANSERIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:48:52.917943+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:48:58.304979+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KETANSERIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:48:58.673648+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1256709/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:48:59.377719+00:00"}},"allNames":"ketensin","offLabel":[],"synonyms":["R 41 468","ketanserin","ketensin","suffrexal","ketanserin tartrate hydrate","ketanserin tartrate","R 41468"],"timeline":[{"date":"1985-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1985-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Ketensin","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"HTR1F","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1F","protein":"5-hydroxytryptamine receptor 1F"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"}],"modality":"Small Molecule","drugClass":"ketanserin","explanation":"","oneSentence":"","technicalDetail":"Ketanserin acts as a selective antagonist at the 5-HT2A receptor, which is a subtype of serotonin receptor. This blockade results in decreased vascular smooth muscle contraction and subsequent reduction in blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1524","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=KETANSERIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KETANSERIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:12:51.966957","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:49:00.949176+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"benzphetamine","drugSlug":"benzphetamine","fdaApproval":"1960-10-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"deserpidine","drugSlug":"deserpidine","fdaApproval":"1957-04-19","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"deutetrabenazine","drugSlug":"deutetrabenazine","fdaApproval":"2017-04-03","patentExpiry":"Sep 7, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dexamfetamine","drugSlug":"dexamfetamine","fdaApproval":"1955-09-09","relationship":"same-target"},{"drugName":"lisdexamfetamine","drugSlug":"lisdexamfetamine","fdaApproval":"2007-02-23","patentExpiry":"Aug 30, 2040","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"rescinnamine","drugSlug":"rescinnamine","fdaApproval":"1956-10-31","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"reserpine","drugSlug":"reserpine","fdaApproval":"1955-10-12","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"tetrabenazine","drugSlug":"tetrabenazine","fdaApproval":"2008-08-15","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"valbenazine","drugSlug":"valbenazine","fdaApproval":"2017-04-11","patentExpiry":"Sep 18, 2038","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"ketanserin","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzphetamine","brandName":"benzphetamine","genericName":"benzphetamine","approvalYear":"1960","relationship":"same-target"},{"drugId":"deserpidine","brandName":"deserpidine","genericName":"deserpidine","approvalYear":"1957","relationship":"same-target"},{"drugId":"deutetrabenazine","brandName":"deutetrabenazine","genericName":"deutetrabenazine","approvalYear":"2017","relationship":"same-target"},{"drugId":"dexamfetamine","brandName":"dexamfetamine","genericName":"dexamfetamine","approvalYear":"1955","relationship":"same-target"},{"drugId":"lisdexamfetamine","brandName":"lisdexamfetamine","genericName":"lisdexamfetamine","approvalYear":"2007","relationship":"same-target"},{"drugId":"rescinnamine","brandName":"rescinnamine","genericName":"rescinnamine","approvalYear":"1956","relationship":"same-target"},{"drugId":"reserpine","brandName":"reserpine","genericName":"reserpine","approvalYear":"1955","relationship":"same-target"},{"drugId":"tetrabenazine","brandName":"tetrabenazine","genericName":"tetrabenazine","approvalYear":"2008","relationship":"same-target"},{"drugId":"valbenazine","brandName":"valbenazine","genericName":"valbenazine","approvalYear":"2017","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05964647","phase":"PHASE1","title":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-02-01","conditions":["Healthy"],"enrollment":20,"completionDate":"2025-06-30"},{"nctId":"NCT06796361","phase":"PHASE1","title":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-04-21","conditions":["Healthy"],"enrollment":16,"completionDate":"2026-08"},{"nctId":"NCT06899334","phase":"PHASE1","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-04-01","conditions":["Healthy"],"enrollment":24,"completionDate":"2026-08-01"},{"nctId":"NCT03289949","phase":"PHASE1","title":"The Neurobiological Effect of 5-HT2AR Modulation","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2017-03-03","conditions":["Basic Science"],"enrollment":200,"completionDate":"2030-06-01"},{"nctId":"NCT04849013","phase":"PHASE1","title":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-08-11","conditions":["Healthy"],"enrollment":16,"completionDate":"2023-03-27"},{"nctId":"NCT04558294","phase":"PHASE1","title":"Effect of Ketanserin After LSD Administration","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-10-16","conditions":["Healthy"],"enrollment":24,"completionDate":"2021-09-29"},{"nctId":"NCT03321136","phase":"EARLY_PHASE1","title":"Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-11-28","conditions":["Healthy"],"enrollment":16,"completionDate":"2019-07-11"},{"nctId":"NCT03646318","phase":"PHASE4","title":"Ketanserin Effects on Peripheral Temperature and Lactate","status":"UNKNOWN","sponsor":"Onze Lieve Vrouwe Gasthuis","startDate":"2018-09-01","conditions":["Critical Illness"],"enrollment":120,"completionDate":"2019-05-01"},{"nctId":"NCT00557219","phase":"PHASE3","title":"Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery","status":"TERMINATED","sponsor":"Medical University of Gdansk","startDate":"2008-04","conditions":["Acute Renal Failure"],"enrollment":60,"completionDate":"2015-04"},{"nctId":"NCT02451072","phase":"NA","title":"The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers","status":"COMPLETED","sponsor":"Psychiatric University Hospital, Zurich","startDate":"2015-03","conditions":["Healthy"],"enrollment":25,"completionDate":"2016-01"},{"nctId":"NCT02632877","phase":"PHASE1,PHASE2","title":"Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2014-01","conditions":["Diabetic Foot Ulcer"],"enrollment":60,"completionDate":"2015-12"},{"nctId":"NCT01329887","phase":"PHASE3","title":"The Effect of Ketanserin on the Microcirculation in Sepsis","status":"COMPLETED","sponsor":"Frisius Medisch Centrum","startDate":"2011-03","conditions":["Severe Sepsis","Septic Shock"],"enrollment":10,"completionDate":"2014-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167209","NDDF":"005934","UNII":"97F9DE4CT4","CHEBI":"CHEBI:6123","INN_ID":"5087","RXNORM":"6131","UMLSCUI":"C0022616","chemblId":"CHEMBL1256709","ChEMBL_ID":"CHEMBL51","KEGG_DRUG":"D02363","DRUGBANK_ID":"DB12465","PUBCHEM_CID":"3822","SNOMEDCT_US":"441818008","IUPHAR_LIGAND_ID":"88","SECONDARY_CAS_RN":"83846-83-7","MESH_DESCRIPTOR_UI":"D007650"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"12.0 hours","clearance":"6.7 mL/min/kg","bioavailability":"50%","fractionUnbound":"0.055%","volumeOfDistribution":"3.9 L/kg"},"publicationCount":4724,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C02KD01","allCodes":["C02KD01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1985-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:49:00.949176+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}